Pfizer, Inc. · NYSE:PFE

Pfizer — Lehman Brothers Global Healthcare Conference 2008

17 slides from Pfizer's conference presentation, Mar 19, 2008

  1. Slide 1: Lehman Brothers Global Healthcare Conference

    Lehman Brothers Global Healthcare Conference Martin Mackay President, Global Research & Development March 19, 2008

  2. Slide 2: Cautionary Language

    Cautionary Language The discussions at this meeting will include forward- looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in our 2007 Annual Report on Form 10-K and

  3. Slide 3: R&D Five Point Plan

    R&D Five Point Plan „ Aggressively Deliver the Phase 2 and Phase 3 Portfolio „ Prioritize Our Portfolio to Deliver the Most Value „ Become a Top-Tier Biotherapeutics Company „ Dramatically Raise the Bar on Productivity „ Pursue the Best External Science

  4. Slide 4: Rich In Substrate

    Rich In Substrate „ 85 distinct new molecular entities in our pipeline Š 26 biological programs in preclinical/clinical development „ Pipeline breadth and depth in 10 therapeutic areas „ Aggressive goal to rebuild our Phase 3 portfolio Š Total of 15 - 20 Phase 3 starts 2008 - 2009 Š Phase 3 total pr

  5. Slide 5: Pfizer R&D Pipeline

    Pfizer R&D Pipeline (as of February 28, 2008) Over 300 Discovery Projects Phase 1 Phase 2 Approved 47 Phase 3 37 In Reg. Selzentry 16 2 Lyrica Fibromyalgia fesoterodine (EU) ƒ Accelerating Pipeline with Sharpened Focus on Key Disease Areas ƒ Strong flow of medicines expected to progress from Phase 2

  6. Slide 6: Today's Phase 3 Portfolio

    Today’s Phase 3 Portfolio „ axitinib – Pancreatic Cancer „ PD-332334 – GAD „ tremelimumab – Melanoma „ S,S-reboxetine – Fibromyalgia NMEs „ apixaban – VTE Prevention „ Zithromax/chloroquine – Malaria „ CP-945598 – Obesity New Indications „ apixaban – Atrial Fibrillation /

  7. Slide 7: Potential New Indications Expected To Drive Value

    Potential New Indications Expected To Drive Value Colorectal es nu ve Non Small Cell Lung Re Hepatocellular Carcinoma Breast Renal Cell Carcinoma & Gastrointestinal Stromal Tumor Time

  8. Slide 8: axitinib: Potential New Phase 3 Indications

    axitinib: Potential New Phase 3 Indications Study 1016 ECOG PS 0/1 „ Ongoing Phase 3 trial in 1.0 axitinib+gemcitabine pancreatic cancer (n=63) Median: 7.2 mo „ Anticipate at ASCO 0.8 (95% CI: 6.0, 12.5) Overall Survival Probability Š Additional information on both gemcitabine (n=31) Median: 5.7 mo

  9. Slide 9: Projected 15–20 Phase 3 Starts 2008–2009

    Projected 15–20 Phase 3 Starts 2008–2009 „ PF-3187207 „ PF-885706 – GERD „ PF-868554 „ PF-734200 – Glaucoma – HCV – Diabetes „ PF-299804 – Cancer „ CP-751871 „ PF-4194471 „ PF-4522625 – Lung Cancer „ PH-797804 – RA – HIV – Seasonal Flu NMEs „ PF-4383119 „ IV sulopenem/Oral „ CP-690550 „ UK-453061 –

  10. Slide 10: CP-751871 (IGF-1R Ab): Proof Of Concept Established In 1st Line NSCLC

    CP-751871 (IGF-1R Ab): Proof Of Concept Established In 1st Line NSCLC Carboplatin/Paclitaxel (SOC) Study Treatment-naïve Stage IIIB/IV Design NSCLC patients Carboplatin/Paclitaxel + CP-751 60 Response Rate (%) 50 „ Highly specific fully 40 human antibody 30 „ Well tolerated – high 20 potential to co

  11. Slide 11: CP-690550: JAK-3 Inhibitor

    CP-690550: JAK-3 Inhibitor RA Phase 2a Response Rate 100 80 60 40 20 0 0 2 4 6 Weeks Placebo 5 mg 15 mg 30 mg Phase 2b dose ranging in rheumatoid arthritis ongoing – anticipate Kremer JM et al, ACR 2006 presentation at ACR 2008 Simultaneous Development Programs in Psoriasis, Asthma, Transplant Rejec

  12. Slide 12: PF-4383119 (RN-624): Nerve Growth Factor Inhibitor

    PF-4383119 (RN-624): Nerve Growth Factor Inhibitor Heavy Chain Projected 1st Biotherapeutic for Pain „ Blocks Nerve Growth Factor (NGF) Š Humanized monoclonal antibody NGF „ Efficacy demonstrated in Phase 2 osteoarthritis (OA) pain study „ Favorable safety profile to date Š >600 patients treated Lig

  13. Slide 13: PF-4383119: Osteoarthritis Knee Pain

    PF-4383119: Osteoarthritis Knee Pain Single IV Infusion: Mean Change from Baseline (mm) Over 8 Weeks Panel 1 Panel 2 Baseline Pain = 43–46 mm Baseline Pain = 54–60 mm n=12 n=6 n=6 n=6 n=26 n=27 n=26 0 -5 -10 -15 -20 -25 * -30 * * -35 * Placebo 0.1 mg/kg 0.3 mg/kg 1.0 mg/kg Encouraging Phase 1/2 Effi

  14. Slide 14: Projected 15–20 Submissions 2010–2012

    Projected 15–20 Submissions 2010–2012 „ axitinib – Pancreatic Cancer „ Zithromax/chloroquine „ PF-734200 – Diabetes – Malaria „ S,S-reboxetine „ PD-200390 – Insomnia – Fibromyalgia „ PF-299804 – Cancer „ CP-751871 „ CP-945598 – Obesity „ PF-885706 – GERD – 3rd Line NSCLC NMEs „ PD-332334 – GAD „ PF-

  15. Slide 15: 86 Biotherapeutics In The Pipeline

    86 Biotherapeutics In The Pipeline Research Development Marketed 60 26 5 $1.4 B 2007 Diverse Portfolio Revenues 8 TAs (interferon beta-1a) (dalteparin sodium injection) 6 Modalities 53 MAbs 8 Vaccines (pegvisomant for injection)

  16. Slide 16: Delivery In Action

    Delivery In Action Selzentry/Celsentri Approved for Treatment Experienced HIV (US/EU) Champix, Revatio Approved for Smoking Cessation, PAH (Japan) Zithromax SR Submitted for Bacterial Infections (Japan) Fablyn Submitted for Osteoporosis Spiriva Respimat Submitted for COPD Xalacom Submitted for Glauc

  17. Slide 17: Strong And Growing Portfolio

    Strong And Growing Portfolio New In-Line Established (glipizide) Extended Release Tablets Dynastat ® IV/IM (parecoxib sidico injectable)

Pfizer — Lehman Brothers Global Healthcare Conference 2008 on 6ix